Although stereo-specific monoclonal antibody against cis P-tau is currently in clinical trial, and trehalose has shown promise in treating neurodegenerative diseases, further investigation into the Pin1-cis P-tau-ApoE mechanisms is required in other gestational tissues, as well as transcription and soluble pro- and anti-angiogenic factors, and dyslipidemia-inducing genetic polymorphisms that may influence outcomes like preeclampsia and dementia-like features in the immediate and long term. This evidence concerns the gene MAPT and metabolic syndrome.